合并微血管侵犯的HCC患者术后辅助治疗:现状与前景

Postoperative adjuvant therapy for HCC patients with microvascular invasion:current status and prospect

原发性肝细胞肝癌是世界上常见的恶性肿瘤,手术切除是其首选的治疗方式,但微血管侵犯(MVI)作为其独立的危险因素影响着手术后患者的生存情况。本文介绍了术后MVI阳性对患者预后的影响,同时介绍了目前常用于预防术后复发,改善肝切除患者生存情况的一系列辅助治疗方法,包括放射疗法、肝动脉化疗栓塞术(TACE)、肝动脉灌注化疗(HAIC)、靶向疗法、免疫疗法、抗病毒及营养支持疗法,评述了各类疗法对MVI阳性患者的治疗效果。作者认为,大多数治疗均展现了相应的应用前景,但疗效和适用人群有待进一步探索,而联合治疗可能是未来术后辅助治疗前进的方向。

Primary hepatocellular carcinoma is a common malignant tumor worldwide,and surgical resection remains the first choice of treatment.However,microvascular invasion(MVI)as an independent risk factor affects the survival of pa-tients after surgery.This article introduces the effect of postoperative MVI positive on prognoses and reviews several adju-vant therapy methods commonly used to prevent postoperative recurrence and improve the survival of patients undergoing hepatectomy,including radiotherapy,transcatheter arterial chemoembolization(TACE),hepatic arterial infusion chemo-therapy(HAIC),targeted therapy,immunotherapy,antiviral,and nutritional support therapy.The therapeutic effects of various therapies on MVI positive patients were reviewed.Here,we concluded that most treatments have shown promise,but efficacy and target populations need to be further explored,combined therapy may be the direction of postoperative adju-vant therapy in the future.